Posted: June 4, 2022 at 2:45 am
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro) inhibitor, STI-1558.
See the original post here:
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and...
Posted: June 4, 2022 at 2:45 am
MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that management will participate at two upcoming conferences in June:
The rest is here:
Elucida Oncology to Present at Two Upcoming Conferences
Posted: June 4, 2022 at 2:45 am
See the article here:
Virbac : Declaration of the number of shares and voting rights 05/2022
Posted: June 4, 2022 at 2:45 am
See the article here:
Bavarian Nordic Conference Call: General Monkeypox Update
Posted: June 4, 2022 at 2:45 am
Ad hoc announcement pursuant to Art. 53 LR
Read the original:
Santhera Announces Corporate Calendar Update
Posted: June 4, 2022 at 2:45 am
Saint-Herblain (France), June 3, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies Healthcare Conference which will take place from June 8 to 10, 2022 in New York.
See original here:
Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference
Posted: June 4, 2022 at 2:45 am
See the rest here:
Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2022.
Posted: June 4, 2022 at 2:45 am
SYDNEY, AUSTRALIA, June 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new data from 1st line NSCLC patients (Part A) of the Phase II TACTI-002 trial evaluating Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 114 patients.
Go here to read the rest:
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Posted: June 4, 2022 at 2:45 am
Daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the abstract “The Pan-PPAR agonist lanifibranor improves nonalcoholic steatohepatitis (NASH) and glycemic control” has been selected for poster presentation during the American Diabetes Association’s 82nd Scientific Sessions taking place on June 3-7, 2022 New Orleans, United States.
Original post:
Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association
Posted: June 4, 2022 at 2:45 am
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares (the “ADS”) on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Each Freeline ADS represents one ordinary share with a nominal value of £0.00001. The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until November 28, 2022 (the “Compliance Deadline”), to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the Company’s ADSs meet or exceed $1.00 per ADS for at least ten consecutive business days.
See original here:
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
